ANI Pharmaceuticals Launches Carbamazepine ER Capsules, Targets $65M Market
ANI Pharmaceuticals has launched generic Carbamazepine Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths as a limited-competition alternative to Carbatrol. The drug addresses a U.S. annual market worth approximately $65 million based on February 2026 MAT data, bolstering the company’s Generics portfolio strategy.
1. Product Launch
ANI Pharmaceuticals introduced Carbamazepine Extended-Release Capsules in 100 mg, 200 mg and 300 mg strengths, offering a generic alternative to the reference drug Carbatrol. This launch targets patients requiring stable extended-release dosing for seizure management.
2. Market Opportunity
The U.S. annual sales for carbamazepine extended-release formulations are estimated at $65 million based on February 2026 moving annual total data. Limited competition in this segment presents a clear revenue opportunity for the company’s Generics division.
3. Strategic Impact
This addition strengthens ANI’s Generics portfolio by targeting a niche with restricted competitors and supports its mission to improve patient access to essential medicines. The company expects the launch to contribute to sustainable growth and reinforce its R&D-driven pipeline.